Tatsis Ourania 4
4 · VERTEX PHARMACEUTICALS INC / MA · Filed Feb 18, 2026
Research Summary
AI-generated summary of this filing
Vertex (VRTX) EVP Ourania Tatsis Sells 5,304 Shares
What Happened
- Ourania (Dr.) Tatsis, EVP & Chief Regulatory & Quality Officer at Vertex (VRTX), disposed of a total of 5,304 shares on Feb 13, 2026. Of those, 3,804 shares were surrendered to satisfy an exercise price or tax liability (code F) at $487.76 each ($1,855,439), and 1,500 shares were sold in the open market (code S) at a weighted average of about $499.99 each ($749,985). Combined proceeds were roughly $2.61 million. These transactions are sales/withholdings (not purchases).
Key Details
- Transaction dates: February 13, 2026; filing date: February 18, 2026 (filing appears timely).
- Prices & values:
- 3,804 shares @ $487.76 = $1,855,439 (reported as payment of exercise price or tax withholding; code F)
- 1,500 shares @ weighted avg ~$499.99 (range $499.99–$500.04) = $749,985 (open-market sale; code S)
- Total shares disposed: 5,304; total proceeds ≈ $2,605,424.
- Shares owned after transaction: Not specified in the provided filing excerpt.
- Footnotes:
- 10b5-1 plan: The trade(s) were made pursuant to Dr. Tatsis’ company‑approved Rule 10b5‑1 trading plan entered 08/21/2025.
- Open-market sale weighted average price reported; Dr. Tatsis offered to provide per-price share counts upon request.
- Transaction codes explained: F = shares withheld for exercise price/taxes; S = open-market sale.
Context
- The F-code disposition indicates shares were surrendered to cover exercise price or tax liabilities (commonly part of an option exercise or RSU vesting); these are routine administrative dispositions and do not by themselves signal a change in insider sentiment.
- The S-code line was an open-market sale executed under or reported with a 10b5‑1 trading plan, which is a pre-arranged plan that can limit in-the-moment trading decisions.
Insider Transaction Report
Form 4
Tatsis Ourania
EVP, Chief Reg. & Quality Off.
Transactions
- Tax Payment
Common Stock
2026-02-13$487.76/sh−3,804$1,855,439→ 47,632 total - Sale
Common Stock
[F1][F2][F3]2026-02-13$499.99/sh−1,500$749,985→ 46,132 total
Footnotes (3)
- [F1]Transaction made pursuant to Dr. Tatsis' company approved trading plan under Rule 10b5-1, which was entered into on 08/21/2025.
- [F2]Open market sales reported on this line occurred at a weighted average price of $499.99 (range $499.99 to $500.04).
- [F3]Dr. Tatsis undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
Signature
/s/ Christiana Stevenson, Attorney-in-Fact|2026-02-18